Announcements Trials
Browse Landscape

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 41Observational 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pharmacokinetics 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × ALT-803 × Clear all
NCT05981131 2026-04-29

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

ImmunityBio, Inc.

Active not recruiting
6 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04142359 2024-12-10

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Altor BioScience

Terminated
1 enrolled 5 charts

Pharmacokinetics

Data powered by HemOnc (CC BY 4.0) Colophon âš¡